Loss of Phosphatase and Tensin Homolog Protein Expression Is an Independent Poor Prognostic Marker in Lung Adenocarcinoma Naoki Yanagawa, MD, PhD, Charles.

Slides:

Advertisements

Similar presentations

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

Advertisements

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Naomi Fujioka, MD, Christopher A. French, MD, Michael J

Vascular endothelial growth factor expression in non-small-cell lung cancer: Prognostic significance in squamous cell carcinoma Hideyuki Imoto, MD, Toshihiro.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind,

A Novel Classification of MUC1 Expression Is Correlated with Tumor Differentiation and Postoperative Prognosis in Non–Small Cell Lung Cancer Shinjiro.

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Long-Term Outcome after En Bloc Resection of Non–Small-Cell Lung Cancer Invading the Pulmonary Sulcus and Spine Stéphane Collaud, MD, MSc, Thomas K.

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Results of Surgical Treatment for Patients with Small Cell Lung Cancer

Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C

Clinicopathological and Survival Analysis of Japanese Patients with Resected Non- Small-Cell Lung Cancer Harboring NKX2-1, SETDB1, MET, HER2, SOX2, FGFR1,

PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer Hui Yu, MD, PhD, Cory Batenchuk, PhD,

Putative Stem Cell Markers in Non–Small-Cell Lung Cancer: A Clinicopathologic Characterization Willam Sterlacci, MD, Spasenija Savic, MD, Michael Fiegl,

Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer Hidenobu Ishii, MD,

Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated.

Bright-Field Dual-Color Chromogenic In Situ Hybridization for Diagnosing Echinoderm Microtubule-Associated Protein-Like 4-Anaplastic Lymphoma Kinase-Positive.

Membrane Carbonic Anhydrase IX Expression and Relapse Risk in Resected Stage I–II Non–Small-Cell Lung Cancer David J. Stewart, MD, Maria I. Nunez, MD,

Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer Daniel Morgensztern, MD, Saiama.

Keith M. Kerr, MBChB, FRCPath, Ming-Sound Tsao, MD, PhD, Andrew G

PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer Denis Soulières, MD, Fred R.

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK- Rearranged Lung Adenocarcinomas Lynette M. Sholl, MD, Stanislawa Weremowicz,

Aberrant Wnt1/β-Catenin Expression is an Independent Poor Prognostic Marker of Non- small Cell Lung Cancer After Surgery Xianhua Xu, MD, Ping-Li Sun,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Interstitial tumor-associated macrophages combined with tumor-derived colony- stimulating factor-1 and interleukin-6, a novel prognostic biomarker in non–small.

Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline J Noble,

Lung Cancer and Prognosis in Taiwan: A Population-Based Cancer Registry Bing-Yen Wang, MD, Jing-Yang Huang, Ching-Yuan Cheng, MD, Ching-Hsiung Lin, MD,

A Novel EML4-ALK Variant: Exon 6 of EML4 Fused to Exon 19 of ALK

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Characterization of Lymphomas Developing in Immunodeficient Mice Implanted With Primary Human Non–Small Cell Lung Cancer Thomas John, MBBS, PhD, Naoki.

Phase 2 Study of Pemetrexed and Itraconazole as Second-Line Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer Charles M. Rudin, MD, PhD,

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

New IASLC/ATS/ERS Classification and Invasive Tumor Size are Predictive of Disease Recurrence in Stage I Lung Adenocarcinoma Naoki Yanagawa, MD, PhD,

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small.

High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer Heounjeong Go, MD, Yoon Kyung Jeon, MD, PhD, Hyo Jin.

Clinical Significance of Epidermal Growth Factor Receptors in Non-small Cell Lung Cancer and a Prognostic Role for HER2 Gene Copy Number in Female Patients

A Comprehensive Analysis of p16 Expression, Gene Status, and Promoter Hypermethylation In Surgically Resected Non-small Cell Lung Carcinomas William.

The Prognostic Value of Chromosome 7 Polysomy in Non-small Cell Lung Cancer Patients Treated with Gefitinib Lela E. Buckingham, PhD, John S. Coon, MD,

Erratum Journal of Thoracic Oncology

Tumor Spread through Air Spaces Affects the Recurrence and Overall Survival in Patients with Lung Adenocarcinoma >2 to 3 cm Chenyang Dai, MD, Huikang.

Survival Differences by Gender for Resected Non-small Cell Lung Cancer: A Retrospective Analysis of 12,509 Cases in a Japanese Lung Cancer Registry Study

NUT Rearrangement is Uncommon in Human Thymic Epithelial Tumors

Loss of p16INK4A Expression and Homozygous CDKN2A Deletion Are Associated with Worse Outcome and Younger Age in Thymic Carcinomas Scott W. Aesif, MD,

Prognostic Impact of Node Involvement Pattern in Pulmonary pN1 Squamous Cell Carcinoma Patients Masayuki Nakao, MD, Junji Yoshida, MD, PhD, Genichiro.

Rachel Benamore, MB BChir, MRCP, FRCR, Frances A

ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers Samuel J. Klempner, MD, David W. Cohen, MD, Daniel.

Prognostic Impact of Immune Microenvironment in Lung Squamous Cell Carcinoma Kyuichi Kadota, MD, PhD, Jun-ichi Nitadori, MD, PhD, Hideki Ujiie, MD, Daniel.

Tumor-Stroma Ratio Is an Independent Predictor for Survival in Esophageal Squamous Cell Carcinoma kai Wang, MD, Wei Ma, MD, Jianbo Wang, MD, Liang Yu,

Ly6/uPAR-Related Protein C4

Prognostic and Predictive Role of the VeriStrat Plasma Test in Patients with Advanced Non–Small-Cell Lung Cancer Treated with Erlotinib or Placebo in.

Impact of HER2 Gene and Protein Status on the Treatment Outcome of Cisplatin-Based Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer

Significance of Smoking as a Postoperative Prognostic Factor in Patients with Non- small Cell Lung Cancer Takeshi Hanagiri, MD, PhD, Kenji Sugio, MD,

Carcinoma of the esophagus: Prognostic significance of histologic type

Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study Giorgio V.

Pharmacogenetic and Germline Prognostic Markers of Lung Cancer

Thymidylate Synthase Protein Expression by IHC and Gene Copy Number by SISH Correlate and Show Great Variability in Non–Small Cell Lung Cancer Murry.

The Clinical Impact of Solid and Micropapillary Patterns in Resected Lung Adenocarcinoma Naoki Yanagawa, MD, PhD, Satoshi Shiono, MD, PhD, Masami Abiko,

Elevated Expression of BIRC6 Protein in Non–Small-Cell Lung Cancers is Associated with Cancer Recurrence and Chemoresistance Xin Dong, MD, Dong Lin,

Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung.

Tissue Heterogeneity of EGFR Mutation in Lung Adenocarcinoma

An International Interpretation Study Using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance between ALK IHC and.

Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A

ALK Status Testing in Non–Small-Cell Lung Carcinoma by FISH on ThinPrep Slides with Cytology Material Eugen C. Minca, MD, PhD, Christopher P. Lanigan,

Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey.

Presentation transcript:

Loss of Phosphatase and Tensin Homolog Protein Expression Is an Independent Poor Prognostic Marker in Lung Adenocarcinoma Naoki Yanagawa, MD, PhD, Charles Leduc, MD, Derek Kohler, MD, Mauro A. Saieg, MD, PhD, Thomas John, MBBS, PhD, Jenna Sykes, MSc, MMath, Maisa Yoshimoto, MSc, PhD, Melania Pintilie, MSc, Jeremy Squire, PhD, Frances A. Shepherd, MD, FRCPC, Ming-Sound Tsao, MD, FRCPC Journal of Thoracic Oncology Volume 7, Issue 10, Pages 1513-1521 (October 2012) DOI: 10.1097/JTO.0b013e3182641d4f Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Representative images of PTEN immunohistochemistry. A, Low magnification and (B) high magnification, tumor showing complete lack of staining for PTEN. C, Low magnification and (D) high magnification, tumor showing positive staining for PTEN. PTEN, phosphatase and tensin homolog. Journal of Thoracic Oncology 2012 7, 1513-1521DOI: (10.1097/JTO.0b013e3182641d4f) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Representative photographs (100× magnification) of dual-color fluorescent in situ hybridization of non–small-cell lung tumors using probes for PTEN (green/FITC) and the centromere of chromosome 10 centromeric probe (blue/aqua), with grayscale 6-diamidino-2-phenylindole nuclear stain: A, PTEN diploidy; (B), PTEN hemizygous loss as predominant pattern; (C), PTEN hemizygous loss with chromosome 10 monosomy as predominant pattern; (D), PTEN homozygous loss as predominant pattern. PTEN, phosphatase and tensin homolog. Journal of Thoracic Oncology 2012 7, 1513-1521DOI: (10.1097/JTO.0b013e3182641d4f) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Kaplan–Meier DFS curves based on PTEN immunohistochemistry status. A, All patients based on PTEN status showing PTEN negative tumors were associated with poorer DFS compared with PTEN positive tumors. Adenocarcinomas (B) and (C) squamous cell carcinoma, according to PTEN status demonstrating significant differences in DFS based on histology. PTEN, phosphatase and tensin homolog; DFS, disease-free survival; CI, confidence interval; HR, hazard ratio. Journal of Thoracic Oncology 2012 7, 1513-1521DOI: (10.1097/JTO.0b013e3182641d4f) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions